Regeneron Shares Fall After Mixed Results in COPD Drug Trials

Published 2 days agoREGN

Regeneron Shares Fall After Mixed Results in COPD Drug Trials

Regeneron Pharmaceuticals saw a decline in its shares by 9% following the release of mixed results from late-stage trials of its experimental drug, itepekimab. This drug, developed in collaboration with Sanofi, is aimed at treating chronic obstructive pulmonary disease (COPD). Reuters reported on the trials, with one study of 1,127 patients showing a 27% reduction in disease flare-ups over 52 weeks compared to a placebo. However, a second study did not meet its primary endpoint, casting doubt on the drug's approval prospects.

The market reacted to this news, with Regeneron's stocks trading at $549.69, reflecting a 15% decline this year so far. Sanofi's shares also dipped nearly 5% in premarket trading. Analysts express skepticism about the drug's path forward, with Emily Field from Barclays hinting at the challenge of securing approval with these results, and Richard Vosser from J.P. Morgan suggesting that further studies may be needed.

Itepekimab aims to counteract inflammation by inhibiting the interleukin-33 protein, a factor in COPD. The drug was anticipated to reach up to $5 billion in peak annual sales, potentially addressing a larger patient market than Dupixent, another treatment by Regeneron and Sanofi that's already approved for COPD. Following the trials' outcomes, it seems Dupixent will maintain its position as the go-to treatment.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Emirates President Sees Positive Changes at Boeing Amidst Supply Chain Woes

Emirates President Sees Positive Changes at Boeing Amidst Supply Chain Woes

28 minutes agoBA

Emirates' President Tim Clark has signaled a shift in sentiment towards Boeing, citing improvements driven by the company's new CEO. Despite having criticized Boeing for delays with the 777X aircraft—of which Emirates has placed 205 orders—Clark now notes a more promising outlook for the aviation giant. Reuters reported this development as reflective of Boeing’s renewed commitment and efforts to meet its production targets. Nonetheless, Clark has urged aerospace manufacturers to own up to enduring supply chain issues, which he believes extend beyond the lingering effects of the pandemic. Clark highlighted similar delivery delays from Airbus, which could stretch out for an additional three years. His comments underscore the persistent challenges facing the aviation industry as manufacturers struggle to streamline production processes and meet airline expectations. Clark also touched on tariffs, stating that Emirates hasn't witnessed significant demand changes and anticipates GE Aerospace will handle much of the tariff-induced pressures. He expressed criticism toward Rolls-Royce over engine durability but remains open to future collaborations, particularly concerning the Airbus A350-1000, contingent on performance improvements. As Emirates continues to expand, these insights reflect their strategic considerations in navigating the complexities of the global aviation supply chain.

E.l.f. Beauty Stays Committed to China Amid Tariff Challenges

E.l.f. Beauty Stays Committed to China Amid Tariff Challenges

44 minutes agoELF

E.l.f. Beauty has decided to maintain its manufacturing footprint in China, even as the U.S. imposes a new 10% tariff on Chinese imports. This move affects the company's products manufactured in China. NBC New York reported that despite the challenges, CEO Tarang Amin expressed relief that the tariffs were kept at 10% and not increased to the previously suggested 60%. In response to earlier tariffs, E.l.f. Beauty raised prices on a third of its products by $1 and is currently reevaluating its pricing strategy to address the new 10% tariff. The company has also been working on diversifying its supply chain, having decreased its dependency on Chinese manufacturing from almost 100% to around 80%, as noted by Retail Dive. Looking ahead, E.l.f. Beauty intends to incorporate the impact of these tariffs into its fiscal 2026 outlook by exploring strategies such as supplier concessions and cost savings. While the company's focus remains on China for manufacturing, its strategic adjustments aim to sustain its competitive edge in the market.

Eli Lilly Acquires SiteOne Therapeutics and Invests in New Drug Innovations

Eli Lilly Acquires SiteOne Therapeutics and Invests in New Drug Innovations

Eli Lilly recently announced its acquisition of SiteOne Therapeutics in a deal valued at up to $1 billion, as reported by Reuters. This acquisition provides Lilly access to an experimental non-opioid pain treatment called STC-004, which aims to target the Nav1.8 channels involved in transmitting pain signals, potentially offering a breakthrough in pain management without the use of opioids. In addition, Lilly's development of Orforglipron, a new oral medication for diabetes and weight management, is showing promising results in phase 3 trials. The once-daily pill works by leveraging the GLP-1 mechanism to effectively lower blood sugar levels and promote weight loss. Furthermore, Eli Lilly has taken legal steps to protect their products, including filing lawsuits against organizations allegedly selling non-FDA approved compounded versions of its drugs, emphasizing patient safety concerns. To bolster its research capabilities, Eli Lilly is investing $250 million into a long-term partnership with Purdue University. This collaboration is expected to advance drug discovery and manufacturing, using artificial intelligence and other cutting-edge technologies. Together with plans for a new manufacturing facility and an intriguing partnership with OpenAI to discover antibiotics, Eli Lilly continues to chart a path of innovation and strategic growth.

AstraZeneca's Camizestrant Shows Promise in Breast Cancer Treatment

AstraZeneca's Camizestrant Shows Promise in Breast Cancer Treatment

AstraZeneca's new experimental drug, camizestrant, has shown substantial promise in reducing the risk of breast cancer progression when used as part of a treatment guided by blood tests. This was revealed in a study presented at the American Society of Clinical Oncology meeting, which involved a substantial cohort of 3,256 patients who have advanced hormone receptor-positive, HER2-negative breast cancer, according to Reuters. The trial, focusing on a specific segment of 315 patients with ESR1 mutations, found noteworthy results. These mutations are known indicators of resistance to therapy. Patients in the trial were randomly placed into two groups: one group received camizestrant combined with a CDK4/6 inhibitor, while the other group continued with the standard breast cancer treatment. Significantly, patients on the camizestrant regimen experienced a median progression-free survival rate of 16 months, compared to just 9.2 months for those sticking with existing treatments—a 56% reduction in the risk of progression. This study not only highlights the effectiveness of camizestrant but also underscores a new paradigm for treatment, using liquid biopsy blood tests to guide clinical decisions before tumors become detectable via conventional imaging methods. This approach represents a significant potential advancement in how advanced breast cancer can be managed and treated, offering earlier and more effective intervention options for patients.